Retatrutide

Retatrutide
£100.00

Retatrutide is an experimental, once-weekly injectable "triple agonist" (GIP, GLP-1, and glucagon receptor) developed by Eli Lilly for obesity and type 2 diabetes. Currently in Phase 3 trials, it has shown superior weight loss results (up to ~24% in 48 weeks) compared to current GLP-1s, earning it the nickname "triple-G".NEJM +4

Key Details About Retatrutide:

    • Mechanism of Action: It mimics three hormones: GLP-1 (appetite suppression), GIP (improves insulin response), and Glucagon (increases energy expenditure/fat burning).

 

  • Trial Results: Phase 2 studies showed up to 24.2% body weight reduction in participants after 48 weeks of treatment at higher doses, often referred to as "triple G".
  • Availability: It is not yet FDA approved or available to the public. Phase 3 trials are expected to be completed in 2026, with anticipation of approval following soon after.
  • Side Effects: Similar to other weight loss medications, it may cause nausea, diarrhea, vomiting, and constipation.
  • Compared to Others: It is different from semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) because it targets three receptors instead of one or two.